10-QPeriod: Q1 FY2017

Merck & Co., Inc. Quarterly Report for Q1 Ended Mar 31, 2017

Filed May 9, 2017For Securities:MRK

Summary

Merck & Co., Inc. reported strong financial performance for the first quarter of 2017, with total sales reaching $9.4 billion, a 1% increase year-over-year. This growth was primarily driven by significant contributions from Keytruda in the oncology franchise and the strong performance of the Zepatier hepatitis C treatment, along with a boost from the reintegration of European vaccine sales previously managed through a joint venture. The company also saw positive momentum in its Animal Health division. Despite headwinds from generic competition impacting certain established products like Zetia and Januvia/Janumet, Merck demonstrated resilience through its growing portfolio and strategic initiatives. Net income attributable to Merck & Co., Inc. saw a substantial increase to $1.55 billion ($0.56 per share) from $1.13 billion ($0.41 per share) in the prior year's comparable period. This improvement reflects strong sales performance and effective cost management, though offset by increased restructuring costs and research and development expenses. The company also repurchased $1.0 billion of its stock in the quarter, demonstrating a commitment to returning value to shareholders. Overall, the results indicate a positive trajectory driven by key growth products and strategic portfolio adjustments.

Financial Highlights

51 data points
Beta

Revenue

$9.43B

67.7% Gross Margin

Net Income

$1.55B

16.4% Net Margin

EPS (Diluted)

$0.56

Total Assets

$96.56B

Cash & Equivalents

$11.71B

Free Cash Flow

$286.00M

Financial Statements
Beta
Revenue$9.43B
Cost of Revenue$3.05B
Gross Profit$6.38B
R&D Expenses$1.83B
SG&A Expenses$2.47B
Interest Expense$182.00M
Net Income$1.55B
EPS (Basic)$0.56
EPS (Diluted)$0.56
Shares Outstanding (Basic)2.75B
Shares Outstanding (Diluted)2.77B

Key Highlights

  • 1Total sales increased by 1% to $9.4 billion in Q1 2017 compared to Q1 2016, driven by Keytruda, Zepatier, and vaccine sales from the former SPMSD joint venture.
  • 2Net income attributable to Merck & Co., Inc. rose to $1.55 billion ($0.56/share) from $1.13 billion ($0.41/share) year-over-year.
  • 3Keytruda sales surged to $584 million from $249 million in the prior year's quarter, signaling strong momentum in the oncology segment.
  • 4Zepatier sales increased significantly to $378 million from $50 million, reflecting successful global launches.
  • 5The termination of the Sanofi Pasteur MSD (SPMSD) joint venture on December 31, 2016, allowed Merck to record European vaccine sales directly, contributing approximately $65 million in incremental sales.
  • 6Animal Health segment sales grew by 13% to $939 million, boosted by products like Bravecto.
  • 7The company repurchased $1.0 billion of its common stock in Q1 2017, underscoring its commitment to shareholder returns.

Frequently Asked Questions

Sales growth was primarily driven by strong performance in the oncology franchise, particularly Keytruda, the successful global launches of the hepatitis C treatment Zepatier, and the reintegration of European vaccine sales following the termination of the SPMSD joint venture. The Animal Health division also contributed positively.

Several products experienced sales declines due to factors such as generic competition (e.g., Zetia losing U.S. market exclusivity), pricing pressures, and competitive dynamics. Notable declines were seen in Zetia, Januvia/Janumet, Cubicin, Remicade, and Singulair.

Merck returned value to shareholders through a quarterly dividend of $0.47 per share and continued its share repurchase program, buying back $1.0 billion of its common stock in the first quarter of 2017, with $4.0 billion remaining under its authorized repurchase program.

Merck is involved in various legal proceedings, including product liability lawsuits related to Fosamax, Januvia/Janumet, and Propecia/Proscar, as well as patent litigation and commercial disputes. While the company believes these are normal to its business and unlikely to be material in aggregate, specific outcomes, particularly in ongoing patent disputes and product liability cases, could potentially impact financial results.